Wednesday, September 16, 2026
60 articles analyzed
Updated Sep 16, 9:00 PM · 60 sources analyzed
Key Takeaways
Abivax completed both Phase 3 ABTECT ulcerative colitis trials; top-line data not yet disclosed — readout is the near-term catalyst.
Ryvu Therapeutics terminated its Phase 2 RVU120 myelofibrosis study; termination rationale undisclosed and warrants investor follow-up.
Erasca's ERAS-007/ERAS-601 combo study completed with no data released; conference presentation is the next signal for RAS/MAPK franchise.
🏆 Winner
Apnimed — completed the pivotal SynAIRgy Phase 3 OSA study, positioning for a potential first-in-class oral pharmacotherapy NDA in a large, device-dominated market.
📉 Loser
Ryvu Therapeutics — Phase 2 termination of RVU120 in myelofibrosis without a disclosed rationale raises questions about CDK8/19 viability in hematologic malignancies.
🔭 Watch Next
Abivax's top-line data disclosure from ABTECT-1 and ABTECT-2 is the most consequential near-term event visible in today's sources, likely targeting a major gastroenterology congress in late 2026 or early 2027.
Erasca ERAS-007 + ERAS-601 combo trial marked complete
Erasca's Phase 1/2 study evaluating ERAS-007 (an ERK inhibitor) as monotherapy or in combination with ERAS-601 (a SHP2 inhibitor) in advanced or metastatic solid tumors has been marked completed on ClinicalTrials.gov. No efficacy or safety data have been released publicly alongside this status change, leaving investors without a signal on whether the combination generated meaningful tumor control. For a company whose RAS/MAPK pathway franchise is the core of its investment thesis, the absence of accompanying data disclosure means the market will need to wait for a conference presentation or publication before updating any probability of success estimates.
ClinicalTrials.gov ↗Abivax S.A.
ABX464 (obefazimod) in Moderately to severely active ulcerative colitis
Both ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) Phase 3 trials evaluating ABX464 at 25 mg or 50 mg once daily versus placebo for clinical remission induction have been marked completed on ClinicalTrials.gov. Full efficacy and safety data have not been released alongside this registry update.
Why it matters
Two concurrent Phase 3 completions in the same indication is a material milestone for a small-cap company, but the investment thesis hinges entirely on what the data show — particularly whether the dose-response between 25 mg and 50 mg is meaningful and whether tolerability holds up. Until top-line numbers are disclosed, the registry update alone moves no models.
What to watch
Watch for Abivax's top-line press release from ABTECT-1 and ABTECT-2, expected to be presented at a major gastroenterology meeting such as United European Gastroenterology Week or Crohn's & Colitis Congress in late 2026 or early 2027.
Apnimed
AD109 in Obstructive sleep apnea (OSA)
The SynAIRgy Phase 3 randomized, double-blind, placebo-controlled, 6-month parallel-arm study comparing fixed-dose combination AD109 to placebo in OSA has been marked completed on ClinicalTrials.gov. Full efficacy data have not been released alongside this registry update.
Why it matters
Apnimed's AD109 is one of the most closely watched assets in sleep medicine given the size of the OSA population and the lack of approved pharmacological alternatives to CPAP — completion of the pivotal study is a necessary precursor to any NDA filing, and the data read will determine whether the company is a serious regulatory candidate or needs to reconsider its dose or population strategy.
What to watch
Watch for Apnimed's top-line SynAIRgy data disclosure and any announcement of an NDA filing timeline, likely targeted for a major sleep or respiratory medicine conference in late 2026.
Ryvu Therapeutics SA
RVU120 (SEL120) in Intermediate or high-risk myelofibrosis
The Phase 2 study of RVU120 (a CDK8/19 inhibitor) in intermediate or high-risk primary or secondary myelofibrosis has been marked terminated on ClinicalTrials.gov. No efficacy or safety data have been released alongside this status change; the reason for termination has not been disclosed in the registry entry.
Why it matters
A terminated Phase 2 in myelofibrosis without a disclosed rationale is a yellow flag for Ryvu's CDK8/19 program — investors will want to know whether the stop was driven by safety, futility at an interim analysis, or strategic portfolio prioritization, because the answer materially changes the asset's residual value and the company's pipeline credibility.
What to watch
Watch for Ryvu to issue a formal statement explaining the termination rationale and clarifying whether RVU120 development continues in any other indication or combination strategy.
Allosteric pathways determine G protein coupling selectivity at promiscuous GPCRs
A new preprint from bioRxiv identifies specific allosteric communication pathways within G protein-coupled receptors (GPCRs — cell surface proteins that relay signals inside cells) that govern which G protein subtype a receptor preferentially activates, even when the receptor can engage multiple G proteins.
Why it matters
GPCRs are the target class for roughly one-third of approved drugs, and biased agonism has been a long-sought but difficult-to-achieve goal — structural insights into allosteric selectivity pathways could meaningfully accelerate structure-based drug design campaigns in cardiovascular, CNS, and metabolic disease programs where on-target toxicity limits dose.
What to watch
Watch for whether this structural framework is adopted by GPCR-focused drug developers and validated in a peer-reviewed journal with experimental mutagenesis data, which would be the next step toward clinical translation.
Both ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) Phase 3 trials evaluating ABX464 at 25 mg or 50 mg once daily versus placebo for clinical remission induction have been marked completed on ClinicalTrials.gov. Full efficacy and safety data have not been released alongside this registry update.
Why it matters
Ulcerative colitis is a crowded market with approved IL-23 inhibitors, S1P modulators, and JAK inhibitors; Abivax will need robust remission and endoscopic improvement rates to carve out a commercial position against entrenched competitors.
Analysis
Two concurrent Phase 3 completions in the same indication is a material milestone for a small-cap company, but the investment thesis hinges entirely on what the data show — particularly whether the dose-response between 25 mg and 50 mg is meaningful and whether tolerability holds up. Until top-line numbers are disclosed, the registry update alone moves no models.
What to watch
Watch for Abivax's top-line press release from ABTECT-1 and ABTECT-2, expected to be presented at a major gastroenterology meeting such as United European Gastroenterology Week or Crohn's & Colitis Congress in late 2026 or early 2027.
The SynAIRgy Phase 3 randomized, double-blind, placebo-controlled, 6-month parallel-arm study comparing fixed-dose combination AD109 to placebo in OSA has been marked completed on ClinicalTrials.gov. Full efficacy data have not been released alongside this registry update.
Why it matters
OSA pharmacotherapy is a significant unmet need with no FDA-approved oral drug combination; a successful Phase 3 read for AD109 would open a large and largely untapped market currently dominated by CPAP devices.
Analysis
Apnimed's AD109 is one of the most closely watched assets in sleep medicine given the size of the OSA population and the lack of approved pharmacological alternatives to CPAP — completion of the pivotal study is a necessary precursor to any NDA filing, and the data read will determine whether the company is a serious regulatory candidate or needs to reconsider its dose or population strategy.
What to watch
Watch for Apnimed's top-line SynAIRgy data disclosure and any announcement of an NDA filing timeline, likely targeted for a major sleep or respiratory medicine conference in late 2026.
The Phase 1/2 study of ERAS-007 (ERK inhibitor) as monotherapy and in combination with ERAS-601 (SHP2 inhibitor) in advanced or metastatic solid tumors has been marked completed on ClinicalTrials.gov. No efficacy or safety data have been released alongside this status change.
Why it matters
The RAS/MAPK pathway combination strategy is Erasca's central bet; how this combo performed in terms of tolerability and tumor response versus monotherapy will shape investor confidence in the broader pipeline.
Analysis
Erasca has positioned itself as a RAS/MAPK-focused company, and completing this foundational combination study is a necessary step toward late-stage development — but without data, the watchlist hit carries no new signal for modeling response rates or informing next-phase design decisions.
What to watch
Watch for Erasca to present ERAS-007 plus ERAS-601 combination data at ASCO, AACR, or ESMO in the next one to two conference cycles, which will be the first real test of whether the ERK plus SHP2 mechanistic rationale holds clinically.
Two separate Phase 2 studies of sonelokimab — one in active psoriatic arthritis (NCT05640245) and one in moderate to severe hidradenitis suppurativa (NCT05322473) — have both been marked completed on ClinicalTrials.gov. Full efficacy and safety data have not been released alongside these registry updates.
Why it matters
Sonelokimab is a nanobody targeting IL-17A and IL-17F simultaneously, competing in indications where IL-17 inhibitors are already established; dual Phase 2 completions set the stage for potential Phase 3 initiation if data support advancement.
Analysis
Dual Phase 2 completions across two distinct inflammatory indications signal MoonLake is approaching a critical pipeline decision point — the data from these studies will determine whether the IL-17A/F nanobody format offers a differentiated efficacy or dosing profile over existing IL-17 inhibitors like secukinumab or ixekizumab, which will be the key question for any partnership or financing discussions.
What to watch
Watch for MoonLake to disclose top-line data from both studies and announce Phase 3 initiation plans in psoriatic arthritis or hidradenitis suppurativa, likely within the next one to two quarters.
The Phase 2 study of RVU120 (a CDK8/19 inhibitor) in intermediate or high-risk primary or secondary myelofibrosis has been marked terminated on ClinicalTrials.gov. No efficacy or safety data have been released alongside this status change; the reason for termination has not been disclosed in the registry entry.
Why it matters
Myelofibrosis is a competitive space with JAK inhibitors as standard of care and several next-generation combinations in development; a terminated Phase 2 raises questions about whether RVU120's CDK8/19 mechanism can deliver meaningful clinical benefit in this hematologic malignancy.
Analysis
A terminated Phase 2 in myelofibrosis without a disclosed rationale is a yellow flag for Ryvu's CDK8/19 program — investors will want to know whether the stop was driven by safety, futility at an interim analysis, or strategic portfolio prioritization, because the answer materially changes the asset's residual value and the company's pipeline credibility.
What to watch
Watch for Ryvu to issue a formal statement explaining the termination rationale and clarifying whether RVU120 development continues in any other indication or combination strategy.
Allosteric pathways determine G protein coupling selectivity at promiscuous GPCRs
A new preprint from bioRxiv identifies specific allosteric communication pathways within G protein-coupled receptors (GPCRs — cell surface proteins that relay signals inside cells) that govern which G protein subtype a receptor preferentially activates, even when the receptor can engage multiple G proteins.
Why it matters
Understanding the structural basis of G protein selectivity at promiscuous GPCRs could enable the rational design of biased agonists (drugs that selectively activate beneficial signaling pathways while avoiding those that cause side effects), a strategy that has been elusive for many GPCR drug programs.
Analysis
GPCRs are the target class for roughly one-third of approved drugs, and biased agonism has been a long-sought but difficult-to-achieve goal — structural insights into allosteric selectivity pathways could meaningfully accelerate structure-based drug design campaigns in cardiovascular, CNS, and metabolic disease programs where on-target toxicity limits dose.
What to watch
Watch for whether this structural framework is adopted by GPCR-focused drug developers and validated in a peer-reviewed journal with experimental mutagenesis data, which would be the next step toward clinical translation.
Cannabidiol acts as a negative allosteric modulator of fentanyl-bound mu-opioid receptor
A molecular dynamics study found that cannabidiol (CBD) interacts with the mu-opioid receptor (MOR1) in a state-dependent manner when fentanyl is already bound, functioning as a negative allosteric modulator (NAM — a molecule that reduces receptor activity without occupying the primary drug-binding site) across multiple receptor conformations.
Why it matters
If CBD can dampen opioid receptor signaling when an opioid agonist is present, it may offer a mechanistic basis for combination strategies aimed at reducing opioid-induced side effects such as respiratory depression without fully blocking analgesia.
Analysis
This computational finding adds molecular detail to earlier experimental CBD-MOR1 data, but translating allosteric modulation observed in silico (computer simulation) into a therapeutically viable combination product will require rigorous in vivo dose-finding — companies developing opioid-sparing or overdose-mitigation strategies should track whether this mechanism replicates in animal safety models.
What to watch
Watch for peer-reviewed publication of these findings and whether any clinical-stage company or academic group initiates a pharmacokinetic interaction study of CBD co-administration with opioids in humans.
Free fatty acid receptor 2 modulates NADPH oxidase activity triggered by formyl peptide receptors in neutrophils
A bioRxiv preprint demonstrates that free fatty acid receptor 2 (FFAR2 — a receptor activated by short-chain fatty acids produced by gut bacteria) cross-regulates NADPH oxidase activity (an enzyme complex that generates reactive oxygen species critical for killing pathogens and driving inflammation) induced by formyl peptide receptor agonists in neutrophils.
Why it matters
FFAR2 is an emerging anti-inflammatory target; showing that it can tune neutrophil oxidative burst downstream of formyl peptide receptors opens a potential strategy for modulating innate immune-driven tissue damage in conditions like inflammatory bowel disease, sepsis, or ARDS without broadly suppressing pathogen killing.
Analysis
FFAR2 agonism as an immunomodulatory approach has attracted interest from companies including AstraZeneca, and this mechanistic cross-talk data adds a new layer to the receptor's biology — drug developers targeting the FPR or FFAR2 axes should assess whether combination or biased approaches could exploit this interaction for selective neutrophil modulation.
What to watch
Watch for peer-reviewed publication and any disclosure from FFAR2-focused programs of whether this receptor cross-talk is being incorporated into their mechanistic rationale or clinical biomarker strategy.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Erasca's Phase 1/2 study of ERAS-007 (ERK inhibitor) as monotherapy and in combination with ERAS-601 (SHP2 inhibitor) in advanced solid tumors has been marked completed on ClinicalTrials.gov. No efficacy or safety data have been disclosed alongside the registry status change.
ClinicalTrials.gov ↗Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse